ALNY

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ALNY

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/21	05 : 34	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/05/21	05 : 10	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/05/21	05 : 09	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/05/21	05 : 08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/05/21	05 : 07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/05/21	05 : 06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/05/21	05 : 06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/05/21	05 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/05/21	05 : 04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/05/21	05 : 03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/05/21	05 : 02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/05/07	21 : 00	Business Wire	Alnylam Issues 2023 Corporate Responsibility Report	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/05/02	21 : 00	Business Wire	Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/04/30	20 : 00	PR Newswire (US)	Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/04/30	20 : 00	PR Newswire (Canada)	Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/04/18	21 : 00	Business Wire	Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/04/07	21 : 00	Business Wire	Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/03/20	21 : 00	Business Wire	Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/03/13	20 : 30	Business Wire	Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/03/06	20 : 50	Business Wire	Alnylam meldet positive KARDIA-2 Topline-Studienergebnisse, die eine klinisch signifikante Blutdrucksenkung bei Zugabe von Zilebesiran zu Standard-Blutdrucksenkern belegen	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/03/06	07 : 39	Business Wire	Alnylam annonce des résultats positifs de l’étude KARDIA-2 démontrant des réductions cliniquement significatives de la pression artérielle lorsque le zilebesiran est ajouté à des antihypertenseurs standards	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/03/06	06 : 22	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/03/06	06 : 21	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/03/06	06 : 21	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/03/06	06 : 20	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/03/05	21 : 30	Business Wire	Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/03/05	06 : 33	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/03/01	06 : 18	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/03/01	06 : 18	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc
2024/03/01	06 : 18	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALNY	Alnylam Pharmaceuticals Inc